MedTrace Logo

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

NCT03195673 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-12-11

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in Carotid Artery Stenting

Conditions

  • Carotid Artery Stenosis

Interventions

DRUG

Terazosin

TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.

PROCEDURE

Carotid artery stenting

Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.

Sponsors & Collaborators

  • The Luhe Teaching Hospital of the Capital Medical University

    collaborator OTHER

  • Beijing Anzhen Hospital

    collaborator OTHER

  • Capital Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-02
Primary Completion
2019-11-15
Completion
2019-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03195673 on ClinicalTrials.gov